Literature DB >> 9637726

Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model.

D A Barnes1, J Tse, M Kaufhold, M Owen, J Hesselgesser, R Strieter, R Horuk, H D Perez.   

Abstract

Adjuvant-induced arthritis (AIA) is one of many animal models of rheumatoid arthritis, a disease characterized by a T-lymphocyte and macrophage cellular infiltrate. We have characterized the development of this disease model with respect to chemokine expression. Increased levels of two chemokines, RANTES, a T-lymphocyte and monocyte chemo-attractant, and KC a chemoattractant for neutrophils, were found in whole blood and in the joint. Surprisingly, levels of MIP-1alpha, another T-lymphocyte and monocyte chemoattractant, were unchanged throughout the course of the disease in whole blood and only slightly elevated in the joint. RANTES expression plays an important role in the disease since a polyclonal antibody to RANTES greatly ameliorated symptoms in animals induced for AIA and was found to be as efficacious as treatment with indomethacin, a non-steroidal anti inflammatory. Polyclonal antibodies to either MIP-1alpha or KC were ineffective. This is the first report to show the importance of RANTES in the development of AIA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9637726      PMCID: PMC508883          DOI: 10.1172/JCI2172

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  Low levels of interleukin-4 and high levels of transforming growth factor beta in rheumatoid synovitis.

Authors:  P Miossec; M Naviliat; A Dupuy d'Angeac; J Sany; J Banchereau
Journal:  Arthritis Rheum       Date:  1990-08

2.  HLA-D and Ia antigens in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  P Stastny
Journal:  Arthritis Rheum       Date:  1978-06

3.  Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES.

Authors:  T J Schall; K Bacon; K J Toy; D V Goeddel
Journal:  Nature       Date:  1990-10-18       Impact factor: 49.962

4.  Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis.

Authors:  A Fontana; H Hengartner; E Weber; K Fehr; P J Grob; G Cohen
Journal:  Rheumatol Int       Date:  1982       Impact factor: 2.631

5.  Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis.

Authors:  T Kasama; R M Strieter; N W Lukacs; P M Lincoln; M D Burdick; S L Kunkel
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

Review 6.  The Duffy antigen receptor for chemokines: structural analysis and expression in the brain.

Authors:  R Horuk; A Martin; J Hesselgesser; T Hadley; Z H Lu; Z X Wang; S C Peiper
Journal:  J Leukoc Biol       Date:  1996-01       Impact factor: 4.962

7.  Requirement of MIP-1 alpha for an inflammatory response to viral infection.

Authors:  D N Cook; M A Beck; T M Coffman; S L Kirby; J F Sheridan; I B Pragnell; O Smithies
Journal:  Science       Date:  1995-09-15       Impact factor: 47.728

8.  Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor.

Authors:  K Neote; D DiGregorio; J Y Mak; R Horuk; T J Schall
Journal:  Cell       Date:  1993-02-12       Impact factor: 41.582

9.  Effects of naproxen on connective tissue changes in the adjuvant arthritic rat.

Authors:  N R Ackerman; W H Rooks; L Shott; H Genant; P Maloney; E West
Journal:  Arthritis Rheum       Date:  1979-12

10.  Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis.

Authors:  G S Firestein; W D Xu; K Townsend; D Broide; J Alvaro-Gracia; A Glasebrook; N J Zvaifler
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

View more
  41 in total

Review 1.  New therapies in development for autoimmune diseases: their rationale for combination treatment.

Authors:  V Strand
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Chemokine receptors and neural function.

Authors:  Charlene Cho; Richard J Miller
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

Review 3.  Slit proteins, potential endogenous modulators of inflammation.

Authors:  Necat Havlioglu; Liya Yuan; Hao Tang; Jane Y Wu
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

4.  C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis.

Authors:  S Youssef; G Maor; G Wildbaum; N Grabie; A Gour-Lavie; N Karin
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

Review 5.  Chemokines: their role in rheumatoid arthritis.

Authors:  Clarissa E Vergunst; Paul P Tak
Journal:  Curr Rheumatol Rep       Date:  2005-10       Impact factor: 4.592

Review 6.  G protein betagamma subunits as targets for small molecule therapeutic development.

Authors:  Alan V Smrcka; David M Lehmann; Axel L Dessal
Journal:  Comb Chem High Throughput Screen       Date:  2008-06       Impact factor: 1.339

7.  Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study.

Authors:  Wilco de Jager; Esther P A H Hoppenreijs; Nico M Wulffraat; Lucy R Wedderburn; Wietse Kuis; Berent J Prakken
Journal:  Ann Rheum Dis       Date:  2006-12-14       Impact factor: 19.103

Review 8.  Chemokines in joint disease: the key to inflammation?

Authors:  J J Haringman; J Ludikhuize; P P Tak
Journal:  Ann Rheum Dis       Date:  2004-04-13       Impact factor: 19.103

Review 9.  The role of chemokines in leucocyte-stromal interactions in rheumatoid arthritis.

Authors:  Andrew Filer; Karim Raza; Mike Salmon; Christopher D Buckley
Journal:  Front Biosci       Date:  2008-01-01

10.  Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis.

Authors:  J J Haringman; M C Kraan; T J M Smeets; K H Zwinderman; P P Tak
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.